Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab-associated acute profound thrombocytopenia

Journal of Invasive Cardiology

Volumn 13, Issue 6, 2001, Pages 471-473

  Rao, Jayasree ^a   Mascarenhas, D A N ^a,b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Abciximab; Eptifibatide; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE;

ACUTE DISEASE; AGED; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; CORONARY BLOOD VESSEL; HUMAN; MALE; STENT; THROMBOCYTOPENIA;

ACUTE DISEASE; AGED; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CORONARY VESSELS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; PEPTIDES; PLATELET AGGREGATION INHIBITORS; STENTS; THROMBOCYTOPENIA;

EID: 0035374480     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. The Epilog Investigators. Platelet glycoprotein IIb/IIIa blockade with abciximab and low dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
2. Philips DR, Charo IF, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988;71:831-843.
3. Hynes RO. Integrins: A family of cell surface receptors. Cell 1987;4S:549-554.
4. Philips DR, Scarborough RM. GP IIb/IIIa. The responsive integrin. Cell 1991;65:359-362.
5. Jang Y, Lincoff AM, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol 1994;24:1591-1601.
6. Aguirre F, Topol EJ, Ferguson JJ, et al., for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:288-290.
7. Jubelirer S, Koenig BA, Bates MC, et al. Acute profound thrombocytopenia following c7E3 Fab (abciximab) therapy: Case reports, review of the literature and implications for therapy. Am J Hematology 1999;61:205-208.
8. Berkovitz SD, Sane DC, Sigmon ICN, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol 1998;32:311-319.
9. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330:956-961.
10. Topol EJ, Califf RM, Tcheng JE, et al. Randomised placebo controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: Impact II. Lancet 1997;349:1424-1428.
11. Harrington RA, Kleiman NS, Kottke Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-1227.
12. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.
13. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990;322:33-42.
14. Chong BH. Heparin-induced thrombocytopenia. Aust NZ J Med 1992;22:145-152.
15. Aster RH. Heparin-induced thrombocytopenia. N Engl J Med 1995;332:1374-1376.
16. Berkovitz SD, Harrington RA, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab therapy. Circulation 1997;95:809-813.
17. Tcheng JE, Kereiakes DJ, Braden GA, et al. Readministration of abciximab: Interim report of the ReoPro readministration registry. Am Heart J 1999;138:S33-S38.
18. Frelinger AL, Cohen I, Plow EF, et al. Selective inhibition of integrin function by antibodies specific for ligan occupied receptor conformers. J Biochem 1990;265:6346-6352.
19. Dennis MS, Henzel WJ, Pitti RM. Platelet glycoprotein IIb/IIIa protein antagonists from snake venoms: Evidence for a family of platelet aggregation inhibitors. Proc Natl Acad Sci USA 1990;87:2471-2475.
20. Desai M, Lucore C. Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab associated thrombocytopenia 10 months earlier. J Invas Cardiol 2000;12:109-112.
21. Niem N, Mascarenhas DAN. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab. J Invas Cardiol 2001;13:56-58.
22. Elmi F, Oza R, Mascarenhas DAN. Acute profound thrombocytopenia without bleeding complications after abciximab administration. J Invas Cardiol 1999;11:313-315.